Department of Orthopaedic Surgery, School of Medicine, Washington University, St. Louis, MO, USA.
The Chinese University of Hong Kong, Institute for Tissue Engineering and Regenerative Medicine, Hong Kong SAR, China.
J Orthop Res. 2020 Mar;38(3):485-502. doi: 10.1002/jor.24485. Epub 2020 Jan 29.
Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:485-502, 2020.
基于细胞的疗法，在这里定义为将细胞递送到体内以治疗疾病，最近作为一种有希望恢复肌肉骨骼组织结构和功能的潜在方法引起了越来越多的公众关注。虽然基于细胞的疗法有可能改善肌肉骨骼系统疾病的治疗效果，但也存在误用和夸大这些治疗效果的可能性。医学文献中包含了一些轶事报道和研究，以及基于网络的营销和患者证明，支持基于细胞的治疗。美国骨与矿物研究学会（ASBMR）和矫形研究学会（ORS）都致力于通过严格、可重复和具有临床意义的科学发现来实现基于细胞的疗法的潜力。这两个组织召集了一个多学科和国际工作组，由医生、外科医生和科学家组成，他们是开发和使用基于细胞的疗法的公认专家。该工作组的任务是定义基于细胞的疗法的最新技术，并确定知识和方法上的差距，这些差距应该指导研究议程。该工作组的努力旨在为研究人员和临床医生提供更好的理解，了解当前科学研究的现状，以及为推进基于细胞的疗法在骨骼组织中的研究和应用所需的研究。设计和实施严格、彻底的方案对于利用这些创新疗法和优化临床和功能患者结果将至关重要。除了为临床前和临床研究提供具体建议和伦理考虑外，本报告还概述了如何确定用于骨再生的供体群体的细胞自主和非自主效应的知识差距。©2020 矫形研究学会。由 Wiley 期刊出版公司出版。J Orthop Res 38:485-502, 2020.
